Arzerra ofatumumab: Development discontinued

The partners said GlaxoSmithKline will discontinue development of IV ofatumumab for autoimmune indications to instead focus on a subcutaneous formulation. As a result, further enrollment will be discontinued for a Phase III trial of IV ofatumumab in RA. GSK said it believes the subcutaneous formulation has the "potential to offer added convenience and improved tolerability." The pharma plans to begin a Phase IIb trial of subcutaneous ofatumumab to treat multiple sclerosis next year, while further development of subcutaneous ofatumumab in RA is under review. IV ofatumumab was also in Phase II testing to treat relapsing remitting multiple sclerosis (RRMS). ...